No Data
No Data
Express News | EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Insider Buyers Lose Additional US$59k As EyePoint Pharmaceuticals Dips To US$401m
Mizuho Securities Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Announces Target Price $30
Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session
TD Cowen Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $20
Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and EyePoint Pharmaceuticals (EYPT)